Physician profile
Mark Russell
NPI 1639137540
$6,379.01
in general payments reported to CMS, 2019-2025
37 companies · $801 in 2025
The $801 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $1,115 · 2021: $828 · 2022: $862 · 2023: $1,018 · 2024: $1,138 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,839 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,838.91 |
| Education | $118.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $762.81 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $648.90 | 2020-2025 | Verquvo, Winrevair |
| Novartis Pharmaceuticals Corporation | $623.76 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $415.26 | 2019-2024 | Xarelto |
| Amgen INC. | $382.64 | 2020-2025 | Repatha, Repatha |
| Kestra Medical Technology Services, INC. | $334.13 | 2022-2025 | Assure Wcd |
| Pfizer INC. | $290.34 | 2019-2025 | |
| Abiomed | $287.29 | 2019-2020 | |
| Esperion Therapeutics, INC. | $283.12 | 2020-2024 | Nexletol |
| Amarin Pharma, INC. | $264.13 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $248.37 | 2019-2024 | Farxiga |
| Boston Scientific Corporation | $220.87 | 2019-2023 | Latitude Communicator Power Supply |
| Actelion Pharmaceuticals US, INC. | $209.55 | 2023-2025 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $181.36 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.58 | 2020-2025 | Jardiance |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.